CIM LLC’s ADMA Biologics ADMA Stock Holding History

CIM LLC’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-94,379	Closed	-$1.72M	–	169
2025 Q4	$1.72M	Buy	94,379 +2,893	+3%	+$48.8K	0.23%	83
2025 Q3	$1.34M	Buy	91,486 +665	+0.7%	+$11.4K	0.18%	91
2025 Q2	$1.65M	Buy	+90,821	New	+$1.85M	0.22%	78

Other funds holding ADMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

CIM LLC's ADMA Position: Q1 2026 in Review

CIM LLC sold out of ADMA Biologics (ADMA) in Q1 2026, closing a stake of 94,379 shares — an estimated $1.72M sold.

CIM LLC first reported a position in ADMA in Q2 2025 and held it in 3 quarters. The position peaked at $1.72M in Q4 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

CIM LLC reported no remaining ADMA Biologics position as of Q1 2026 after selling out during the quarter.
CIM LLC sold 94,379 ADMA Biologics shares in Q1 2026, an estimated $1.72M.
CIM LLC first reported a position in ADMA Biologics in Q2 2025 and held it in 3 quarters.
CIM LLC's ADMA Biologics position peaked at $1.72M in Q4 2025.
356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on CIM LLC's 13F filing for Q1 2026, filed 18 May 2026.